MetaCap

Werewolf Therapeutics (HOWL) vs Nomad Power Solutions (NMAD)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Werewolf Therapeutics (HOWL) has outperformed Nomad Power Solutions (NMAD) over the past year, gaining 8.4% versus a loss of 40.6%. Over five years, NMAD leads with a -84.6% price change compared with -93.7% for HOWL. Nomad Power Solutions is the larger company by market cap ($47.2 million vs $46.0 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

HOWL+8.43%NMAD-40.60%
+94%+11%-72%
Nov 21, 20251 yearNov 20, 2026
HOWL-94.08%NMAD-85.12%
+31%-37%-104%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

HOWL versus NMAD key metrics
MetricHOWLNMAD
Share price$0.9466$2.56
Market cap$46.00M$47.15M
1-day change-3.97%+13.53%
YTD return+49.31%-34.86%
1-year return+8.43%-40.60%
5-year return-93.68%-84.58%
EPS (TTM)$-0.58$-1.01
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-60.82M$-6.08M
52-week high$1.20$8.38
52-week low$0.27$2.13
Distance from 52-week high-21.12%-69.45%
Analyst consensusnone—
Avg. price target upside+639.49%—
Average volume1.08M228.96K
Shares outstanding48.60M18.42M
Employees39—
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • HOWL has outperformed NMAD by 49.0 percentage points over the past year.

About Werewolf Therapeutics

HOWL stock →

Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform.

Health Care · Biotechnology: Pharmaceutical Preparations · 39 employees

About Nomad Power Solutions

NMAD stock →

NOMAD Power Solutions, Inc. develops utility-scale mobile energy storage systems on providing transportable solutions.

Health Care · Biotechnology: Pharmaceutical Preparations

HOWL vs NMAD FAQ

Which is bigger, Werewolf Therapeutics or Nomad Power Solutions?

Nomad Power Solutions (NMAD) is larger, with a market capitalization of $47.15M compared with $46.00M for Werewolf Therapeutics (HOWL).

Which stock has performed better over the past year, HOWL or NMAD?

HOWL returned +8.43% over the past 12 months, compared with -40.60% for NMAD (price return, excluding dividends). Past performance does not predict future results.

Are Werewolf Therapeutics and Nomad Power Solutions in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons